Mark Berlacher, MD
Cardiovascular Disease · Ft Wright, KYNPI 1104239797
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,590 of the $3,642 with a category attached, or 71.1%. 8 manufacturers reported payments, led by Edwards Lifesciences at 48.5% of the total. Reporting peaked in 2023 at $2,124 and has fallen 93.2% since, to $144 in 2025.
Across 34 payments — averaging $107.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Siemens Medical Solutions USA, Inc.$848
- Neovasc Medical Inc$565
- Heartflow, Inc.$177
- Abbott$134
- Alnylam Pharmaceuticals Inc.$124
- plus $28 from 2 others
Across 2 payments — averaging $5850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$12K
What the payments were for
- Travel & lodging$2,59071%
- Food & beverage$1,05329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 18 | $1,766 |
| Siemens Medical Solutions USA, Inc. | 8 | $848 |
| Neovasc Medical Inc | 1 | $565 |
| Heartflow, Inc. | 3 | $177 |
| Abbott | 1 | $134 |
| Alnylam Pharmaceuticals Inc. | 1 | $124 |
| Novartis | 1 | $15 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$144
- Quadra Allure MP RF CRT Pacemkr$134
- NAEOTOM Alpha$132
- ONPATTRO$124
How this compares
$3,642 in reported general payments places this provider in the 55th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $563,785 |
| JardianceEmpagliflozin | 324 | $392,541 |
| EntrestoSacubitril/Valsartan | 198 | $237,348 |
| XareltoRivaroxaban | 211 | $221,638 |
| Repatha SureclickEvolocumab | 236 | $214,553 |
| OzempicSemaglutide | 33 | $31,460 |
| FarxigaDapagliflozin Propanediol | 28 | $26,043 |
| Praluent PenAlirocumab | 30 | $22,239 |
| MounjaroTirzepatide | 14 | $18,490 |
| BrilintaTicagrelor | 15 | $11,986 |
| Ezetimibe | 505 | $9,227 |
| Rosuvastatin Calcium | 568 | $7,012 |
| Metoprolol Succinate | 586 | $6,717 |
| Atorvastatin Calcium | 544 | $4,994 |
| Spironolactone | 465 | $3,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $237,348198 claims |
| Novo NordiskOzempic | $13 | $31,46033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Ft Wright
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
- Jeffrey ReichardFlorence$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.